Crossmark

A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL

Crossref DOI link: https://doi.org/10.1038/s41375-019-0573-y

Published Online: 2019-09-17

Published Print: 2020-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Staiger, Annette M. http://orcid.org/0000-0002-5896-3200
,

Altenbuchinger, Michael

Ziepert, Marita

Kohler, Christian

Horn, Heike

Huttner, Michael

Hüttl, Katrin S.

Glehr, Gunther

Klapper, Wolfram http://orcid.org/0000-0001-7208-4117
Szczepanowski, Monika

Richter, Julia http://orcid.org/0000-0002-9543-4084
Stein, Harald

Feller, Alfred C.

Möller, Peter

Hansmann, Martin-Leo

Poeschel, Viola

Held, Gerhard

Loeffler, Markus

Schmitz, Norbert

Trümper, Lorenz

Pukrop, Tobias

Rosenwald, Andreas

Ott, German

Spang, Rainer
License Information

Text and Data Mining valid from 2019-09-17

Version of Record valid from 2019-09-17
More Information

Article History

Received: 4 June 2019

Accepted: 6 June 2019

First Online: 17 September 2019

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below